James G Christensen

James G Christensen

UNVERIFIED PROFILE

Are you James G Christensen?   Register this Author

Register author
James G Christensen

James G Christensen

Publications by authors named "James G Christensen"

Are you James G Christensen?   Register this Author

88Publications

2739Reads

5Profile Views

Enhanced efficacy of sitravatinib in metastatic models of antiangiogenic therapy resistance.

PLoS One 2019 1;14(8):e0220101. Epub 2019 Aug 1.

Department of Experimental Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0220101PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6675057PMC
August 2019

A Transient Pseudosenescent Secretome Promotes Tumor Growth after Antiangiogenic Therapy Withdrawal.

Cell Rep 2018 12;25(13):3706-3720.e8

Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA; Department of Pharmacology and Therapeutics, Roswell Park Comprehensive Cancer Center, Buffalo, NY 14263, USA; Department of Medicine, Roswell Park Comprehensive Cancer Center Buffalo, NY 14263, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.celrep.2018.12.017DOI Listing
December 2018

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

N Engl J Med 2014 Nov 27;371(21):1963-71. Epub 2014 Sep 27.

From the Massachusetts General Hospital Cancer Center (A.T.S., L.P.L., Z.Z., J.W.C., A.J.I.), Dana-Farber Cancer Institute (G.I.S.), and Beth Israel Deaconess Medical Center (D.B.C.) - all in Boston; University of California at Irvine, Irvine (S.-H.I.O.), and Pfizer Oncology, La Jolla (W.T., S.M.S., L.M.T., J.G.C., K.D.W.) - both in California; Seoul National University Hospital, Seoul, South Korea (Y.-J.B.); University of Colorado, Aurora (D.R.C., M.V.-G., R.C.D.); Peter MacCallum Cancer Centre, Melbourne, VIC, Australia (B.J.S.); University of Chicago, Chicago (R.S.); Memorial Sloan Kettering Cancer Center, New York (G.J.R.); Karolinska Institutet, Stockholm (Z.Z.); and Rho, Chapel Hill, NC (P.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1406766DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4264527PMC
November 2014

Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors.

Eur J Cancer 2013 Dec 3;49(18):3936-44. Epub 2013 Sep 3.

Oncogenic Signalling and Growth Control Program, Peter MacCallum Cancer Centre, Locked Bag 1, A'Beckett St, Melbourne, Victoria 8006, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria 3010, Australia; Department of Biochemistry and Molecular Biology, University of Melbourne, Parkville, Victoria 3010, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ejca.2013.08.007DOI Listing
December 2013

Molecular predictors of sensitivity to the insulin-like growth factor 1 receptor inhibitor Figitumumab (CP-751,871).

Mol Cancer Ther 2013 Dec 9;12(12):2929-39. Epub 2013 Oct 9.

Corresponding Author: James G. Christensen, Mirati Therapeutics, 9363 Towne Center Drive, Suite 200, San Diego, CA 92121.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-13-0442-TDOI Listing
December 2013

Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice.

Cancer Res 2013 Jun 10;73(12):3692-703. Epub 2013 Apr 10.

Department of Anatomy, Comprehensive Cancer Center, Cardiovascular Research Institute, University of California-San Francisco, San Francisco, CA 94143, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-12-2160DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3686901PMC
June 2013

Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway.

Cancer Res 2013 Jan 19;73(2):834-43. Epub 2012 Nov 19.

Lowe Center for Thoracic Oncology, Department of Medical Oncology, Dana Farber Cancer Institute, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts 02215, USA.

View Article

Download full-text PDF

Source
http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.
Publisher Site
http://dx.doi.org/10.1158/0008-5472.CAN-12-2066DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3994895PMC
January 2013

Activation of IL-6R/JAK1/STAT3 signaling induces de novo resistance to irreversible EGFR inhibitors in non-small cell lung cancer with T790M resistance mutation.

Mol Cancer Ther 2012 Oct 13;11(10):2254-64. Epub 2012 Aug 13.

Yonsei Cancer Center, Division of Medical Oncology, Department of Internal Medicine, Yonsei University College of Medicine, 250 Seongsanno, Seodaemun-gu, Seoul, Republic of Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-12-0311DOI Listing
October 2012

Biomarker and pharmacologic evaluation of the γ-secretase inhibitor PF-03084014 in breast cancer models.

Clin Cancer Res 2012 Sep 17;18(18):5008-19. Epub 2012 Jul 17.

Oncology Research Unit and Drug Safety, Pfizer Global Research and Development, La Jolla, CA 92129, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-12-1379DOI Listing
September 2012

HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis.

Cancer Lett 2012 Jul 21;320(1):48-55. Epub 2012 Jan 21.

Oncology Research Unit, Pfizer La Jolla, CA 92121, United States.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2012.01.026DOI Listing
July 2012

Pharmacokinetic/pharmacodynamic modeling of crizotinib for anaplastic lymphoma kinase inhibition and antitumor efficacy in human tumor xenograft mouse models.

J Pharmacol Exp Ther 2012 Mar 30;340(3):549-57. Epub 2011 Nov 30.

Pharmacokinetics, Dynamics, and Metabolism, La Jolla Laboratories, Pfizer Worldwide Research and Development, 10777 Science Center Drive, San Diego, CA 92121, USA.

View Article

Download full-text PDF

Source
http://jpet.aspetjournals.org/content/340/3/549.full.pdf
Web Search
http://jpet.aspetjournals.org/cgi/doi/10.1124/jpet.111.18887
Publisher Site
http://dx.doi.org/10.1124/jpet.111.188870DOI Listing
March 2012

An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase inhibitor PF-03814735.

Mol Cancer Ther 2012 Mar 5;11(3):710-9. Epub 2012 Jan 5.

Translational Research, Oncology Research Unit, Pfizer Global R&D, 10777 Science Center Dr. (CB4), San Diego, CA 92121, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-11-0184DOI Listing
March 2012

MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.

Mol Cancer Ther 2012 Mar 11;11(3):660-9. Epub 2012 Jan 11.

Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-11-0754DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4209288PMC
March 2012

Evaluation of the antitumor effects and mechanisms of PF00299804, a pan-HER inhibitor, alone or in combination with chemotherapy or targeted agents in gastric cancer.

Mol Cancer Ther 2012 Feb 1;11(2):439-51. Epub 2011 Dec 1.

Cancer Research Institute, Seoul National University Hospital, Seoul National University College of Medicine, Jongno-gu, Seoul, 110-744, Korea.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-11-0494DOI Listing
February 2012

Proof of principle for crizotinib in anaplastic lymphoma kinase-positive malignancies was achieved in ALK-positive nonclinical models.

Mol Cancer Ther 2011 Nov;10(11):2024

Pfizer Global Research and Development, Precision Medicine, La Jolla, San Diego, CA 92121, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-11-0721DOI Listing
November 2011

Human colon cancer stem cells are enriched by insulin-like growth factor-1 and are sensitive to figitumumab.

Cell Cycle 2011 Jul 15;10(14):2331-8. Epub 2011 Jul 15.

Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, PA, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322474PMC
http://dx.doi.org/10.4161/cc.10.14.16418DOI Listing
July 2011

HGF rescues colorectal cancer cells from EGFR inhibition via MET activation.

Clin Cancer Res 2011 Feb 22;17(3):472-82. Epub 2010 Nov 22.

Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-0568DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033451PMC
February 2011

PF-03732010: a fully human monoclonal antibody against P-cadherin with antitumor and antimetastatic activity.

Clin Cancer Res 2010 Nov 9;16(21):5177-88. Epub 2010 Sep 9.

Translational Research Group in Oncology Research Unit, Pfizer Global Research and Development, La Jolla Laboratories, San Diego, California 92121, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-10-1343DOI Listing
November 2010

Efficacy of c-Met inhibitor for advanced prostate cancer.

BMC Cancer 2010 Oct 14;10:556. Epub 2010 Oct 14.

Department of Urology, Stanford University School of Medicine, Stanford, CA 94305-5328, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2407-10-556DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2964640PMC
October 2010

MGMT modulates glioblastoma angiogenesis and response to the tyrosine kinase inhibitor sunitinib.

Neuro Oncol 2010 Aug 23;12(8):822-33. Epub 2010 Feb 23.

Department of Oncology, Cross Cancer Institute and University of Alberta, 11560 University Avenue, Edmonton, AB, Canada T6G 1Z2.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/neuonc/noq017DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2940678PMC
August 2010

Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency.

Cancer Res 2010 Feb 2;70(4):1625-34. Epub 2010 Feb 2.

Center for Molecular Therapeutics, Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, Massachusetts 02129, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/0008-5472.CAN-09-3620DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3057521PMC
February 2010

PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells.

BMC Cancer 2009 Nov 25;9:411. Epub 2009 Nov 25.

Division of Pediatric Hematology/Oncology, Children's Hospital and University Medical Group of the Greenville Hospital System, Greenville, SC 29605, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1471-2407-9-411DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2790467PMC
November 2009

PF-00477736 mediates checkpoint kinase 1 signaling pathway and potentiates docetaxel-induced efficacy in xenografts.

Clin Cancer Res 2009 Jul 7;15(14):4630-40. Epub 2009 Jul 7.

Oncology Research Unit, Pfizer Global Research and Development, La Jolla Laboratories, San Diego, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-08-3272DOI Listing
July 2009

Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.

Biochemistry 2009 Jun;48(23):5339-49

Pfizer Global Research and Development, La Jolla, Pfizer Inc., 10777 Science Center Drive, San Diego, California 92121, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1021/bi900438wDOI Listing
June 2009

Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis.

Cancer Cell 2009 Mar;15(3):232-9

Molecular and Cellular Biology Research, Sunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ccr.2009.01.021DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4540346PMC
March 2009

HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.

Mol Cancer Ther 2008 Nov 30;7(11):3499-508. Epub 2008 Oct 30.

Department of Surgery, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-08-0374DOI Listing
November 2008

Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models.

Drug Metab Dispos 2008 Jul 1;36(7):1267-74. Epub 2008 Apr 1.

Pharmacokinetics, Dynamics and Metabolism, La Jolla Laboratories, Pfizer Global Research and Development, 10777 Science Center Dr., San Diego, CA 92121, USA.

View Article

Download full-text PDF

Source
http://dmd.aspetjournals.org/cgi/doi/10.1124/dmd.107.019711
Publisher Site
http://dx.doi.org/10.1124/dmd.107.019711DOI Listing
July 2008

Preclinical efficacy of the c-Met inhibitor CE-355621 in a U87 MG mouse xenograft model evaluated by 18F-FDG small-animal PET.

J Nucl Med 2008 Jan 12;49(1):129-134. Epub 2007 Dec 12.

Molecular Imaging Program at Stanford, Bio-X Program, and Department of Radiology, Stanford University, Stanford, California.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2967/jnumed.106.038836DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161137PMC
January 2008

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.

Mol Cancer Ther 2007 Dec;6(12 Pt 1):3314-22

Department of Cancer Biology, Pfizer Global Research and Development, La Jolla Laboratories, 10724 Science Center Drive, La Jolla, CA 92121, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-07-0365DOI Listing
December 2007

Antiangiogenic and anti-invasive effects of sunitinib on experimental human glioblastoma.

Neuro Oncol 2007 Oct 10;9(4):412-23. Epub 2007 Jul 10.

GRECAN, Centre François Baclesse, Universié de Caen Basse-Normandie, 14076 Caen, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1215/15228517-2007-024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1994098PMC
October 2007

Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy.

Proc Natl Acad Sci U S A 2007 Oct 17;104(43):17069-74. Epub 2007 Oct 17.

Sunnybrook Health Sciences Centre, Molecular and Cellular Biology Research, 2075 Bayview Avenue, Toronto, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0708148104DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2040401PMC
October 2007

Sunitinib malate for the treatment of solid tumours: a review of current clinical data.

Expert Opin Investig Drugs 2006 May;15(5):553-61

Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1517/13543784.15.5.5
Publisher Site
http://dx.doi.org/10.1517/13543784.15.5.553DOI Listing
May 2006

Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752.

Proc Natl Acad Sci U S A 2006 Feb 6;103(7):2316-21. Epub 2006 Feb 6.

Cancer Center and Department of Pathology, Molecular Pathology Research Unit, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0508776103DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1413705PMC
February 2006

c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.

Cancer Lett 2005 Jul 11;225(1):1-26. Epub 2004 Nov 11.

Research Pharmacology, Pfizer Inc., La Jolla, CA 92121, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canlet.2004.09.044DOI Listing
July 2005

A selective small molecule c-MET Inhibitor, PHA665752, cooperates with rapamycin.

Clin Cancer Res 2005 Mar;11(6):2312-9

Section of Hematology/Oncology, Department of Medicine, Pritzker School of Medicine, University of Chicago Medical Center, 5841 South Maryland Avenue, Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://clincancerres.aacrjournals.org/content/11/6/2312.full
Web Search
http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0
Publisher Site
http://dx.doi.org/10.1158/1078-0432.CCR-04-1708DOI Listing
March 2005

A novel small molecule met inhibitor induces apoptosis in cells transformed by the oncogenic TPR-MET tyrosine kinase.

Cancer Res 2003 Sep;63(17):5462-9

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.

View Article

Download full-text PDF

Source
September 2003